ORCiD
Adam M. Kaye: 0000-0002-7224-3322
Document Type
Article
Publication Title
Neurology International
ISSN
2035-8385
Volume
13
Issue
1
DOI
10.3390/neurolint13010007
First Page
64
Last Page
78
Publication Date
2-18-2021
Abstract
Valtoco® is a new FDA-approved nasal spray version of diazepam indicated for the treatment of acute, intermittent, and stereotypic episodes of frequent seizure activity in epilepsy patients six years of age and older. Although IV and rectal diazepam are already used to treat seizure clusters, Valtoco® has less variability in plasma concentration compared to rectal diazepam. Furthermore, the intranasal administration of Valtoco® is more convenient and less invasive than rectal or IV diazepam, making it ideal for self-administration outside of a hospital setting. Multiple clinical trials have taken place comparing Valtoco® to the oral, rectal, and IV forms of diazepam. Aside from mild nasal irritation and lacrimation, Valtoco® was found to have no increased safety risk in comparison to traditional forms of diazepam. This review of Valtoco® will include a history of diazepam prescribing and withdrawal treatment, Valtoco® drug information, its mechanism of action, pharmacokinetics and pharmacodynamics, and a comprehensive review of clinical studies.
Recommended Citation
Cornett, E. M.,
Amarasinghe, S. N.,
Angelette, A.,
Abubakar, T.,
Kaye, A. M.,
Kaye, A. D.,
Neuchat, E. E.,
Urits, I.,
&
Viswanath, O.
(2021).
VALTOCO® (Diazepam Nasal Spray) for the Acute Treatment of Intermittent Stereotypic Episodes of Frequent Seizure Activity.
Neurology International, 13(1), 64–78.
DOI: 10.3390/neurolint13010007
https://scholarlycommons.pacific.edu/phs-facarticles/363
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Chemicals and Drugs Commons, Pharmacy and Pharmaceutical Sciences Commons
